Abnormal hedonic process in patients with stable schizophrenia: Relationships to negative symptoms and social functioning.

Qi Zhou, Yue Zheng, Xiaodong Guo, Yi Wang, Chengcheng Pu, Chuan Shi, Xin Yu
Author Information
  1. Qi Zhou: The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.
  2. Yue Zheng: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
  3. Xiaodong Guo: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
  4. Yi Wang: Neuropsychology and Applied Cognitive Neuroscience Laboratory, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
  5. Chengcheng Pu: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
  6. Chuan Shi: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
  7. Xin Yu: Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.

Abstract

Background: Anhedonia is a deficit of dynamic reward process, and a large proportion of schizophrenia patients continue to experience anhedonia even during the stable phase. However, few studies have examined the multiple aspects of performance in reward processing in patients with stable schizophrenia and evidence suggests that physical and cognitive effort may involve different neural mechanisms.
Methods: Parallel measures of effort-based expenditure for reward tasks (EEfRT) and self-report questionnaires of pleasure were applied in 61 patients with stable schizophrenia (SSZ) and 46 healthy controls (HCs), and percentages of hard task choices (HTC%) were used to assess motivation in reward processing. Negative symptoms, neurocognitive and social function were evaluated in SSZ patients, and associations with performance in reward tasks were explored.
Results: SSZ patients reported more severe consummatory and anticipatory anhedonia and social anhedonia. HTC% in reward tasks of SSZ patients were significantly lower than that of HCs, especially in cognitive-effort tasks. HTC% in cognitive tasks were correlated with motivation and pleasure dimension of negative symptoms, whereas HTC% in physical tasks were associated with expression dimension. Anticipatory anhedonia and negative symptoms were correlated with Personal and Social Performance Scale (PSP) scores.
Conclusion: Patients with stable schizophrenia have social anhedonia, physically consummatory and anticipatory anhedonia and reduced reward motivation. They are less willing to make cognitive effort than physical effort for reward. The different associations of physical and cognitive effort with negative symptoms indicate physical and cognitive effort may represent disparate neuropsychological processes. Anticipatory anhedonia is closely related to social functioning.

Keywords

References

  1. Neuropsychiatr Dis Treat. 2020 Feb 21;16:519-534 [PMID: 32110026]
  2. Schizophr Res. 2018 Mar;193:428-434 [PMID: 28811079]
  3. Schizophr Res. 2016 Feb;170(2-3):278-84 [PMID: 26763628]
  4. Schizophr Bull. 2022 Mar 1;48(2):335-346 [PMID: 34891171]
  5. Acta Psychiatr Scand. 2000 Apr;101(4):323-9 [PMID: 10782554]
  6. Schizophr Res. 2020 Sep;223:112-118 [PMID: 32620428]
  7. Psychol Med. 2020 Nov;50(15):2599-2609 [PMID: 31576787]
  8. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57 [PMID: 9881538]
  9. Clin Psychol Sci. 2020 May 1;8(3):555-568 [PMID: 33758684]
  10. Eur Neuropsychopharmacol. 2019 May;29(5):629-642 [PMID: 30879927]
  11. Psychol Med. 2018 Apr;48(6):889-904 [PMID: 28889803]
  12. Schizophr Res. 2015 Feb;161(2-3):382-5 [PMID: 25487699]
  13. Schizophr Res. 2019 Apr;206:277-283 [PMID: 30442476]
  14. Schizophr Res. 2020 Oct;224:133-140 [PMID: 33046339]
  15. Psychiatry Res. 2011 May 15;187(1-2):36-41 [PMID: 21295860]
  16. World Psychiatry. 2018 Jun;17(2):221-222 [PMID: 29856563]
  17. Neuropsychopharmacology. 2015 Mar;40(4):1005-15 [PMID: 25328051]
  18. J Abnorm Psychol. 1976 Aug;85(4):374-82 [PMID: 956504]
  19. Front Psychiatry. 2022 Jan 03;12:766692 [PMID: 35046851]
  20. Front Psychiatry. 2021 Mar 19;12:639536 [PMID: 33815171]
  21. J Abnorm Psychol. 2019 Oct;128(7):710-722 [PMID: 31282687]
  22. Schizophr Bull. 2022 Jun 21;48(4):860-870 [PMID: 35524755]
  23. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Jul;8(7):695-702 [PMID: 36796513]
  24. JAMA Psychiatry. 2019 Mar 1;76(3):314-323 [PMID: 30624573]
  25. Neuroscience. 2015 Apr 16;291:189-202 [PMID: 25686523]
  26. N Engl J Med. 2019 Oct 31;381(18):1753-1761 [PMID: 31665579]
  27. Schizophr Bull. 1987;13(2):261-76 [PMID: 3616518]
  28. Psychiatry Res. 2013 Jan 30;205(1-2):30-5 [PMID: 23021909]
  29. PLoS One. 2009 Aug 12;4(8):e6598 [PMID: 19672310]
  30. Ann Gen Psychiatry. 2015 Sep 03;14:24 [PMID: 26339277]
  31. Neuropsychology. 2016 Sep;30(6):685-96 [PMID: 27054437]
  32. Br J Psychiatry Suppl. 1993 Dec;(22):39-44 [PMID: 8110442]
  33. Front Psychiatry. 2022 Jul 04;13:933642 [PMID: 35859598]
  34. Psychiatry Res. 2010 Jan 30;175(1-2):181-3 [PMID: 19963276]
  35. PLoS One. 2012;7(4):e35352 [PMID: 22530007]
  36. J Abnorm Psychol. 2012 May;121(2):407-15 [PMID: 22149913]
  37. Schizophr Res. 2017 Aug;186:29-38 [PMID: 27230288]
  38. J Psychiatr Res. 2013 Nov;47(11):1590-6 [PMID: 23992770]
  39. JAMA Psychiatry. 2023 Jun 1;80(6):548-557 [PMID: 37043223]
  40. Soc Psychiatry Psychiatr Epidemiol. 2019 Nov;54(11):1343-1351 [PMID: 31456027]
  41. Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):387-96 [PMID: 27107764]
  42. PLoS Biol. 2012 Feb;10(2):e1001266 [PMID: 22363208]
  43. Schizophr Res. 2007 Jul;93(1-3):253-60 [PMID: 17490858]
  44. BMC Psychiatry. 2020 Feb 14;20(1):67 [PMID: 32059664]
  45. J Affect Disord. 2021 Mar 15;283:254-261 [PMID: 33571794]
  46. Eur Neuropsychopharmacol. 2014 May;24(5):725-36 [PMID: 24461724]
  47. J Abnorm Psychol. 2014 May;123(2):387-97 [PMID: 24886012]
  48. Curr Top Behav Neurosci. 2016;27:411-49 [PMID: 26026289]
  49. Schizophr Bull. 2014 Nov;40(6):1328-37 [PMID: 24657876]
  50. J Affect Disord. 2018 Feb;227:192-197 [PMID: 29100151]

Word Cloud

Created with Highcharts 10.0.0rewardpatientsanhedoniataskssymptomsstablephysicalcognitiveeffortsocialschizophreniaSSZHTC%negativemotivationAnhedoniaprocessperformanceprocessingmaydifferentpleasureHCsNegativeassociationsconsummatoryanticipatorycorrelateddimensionAnticipatoryfunctioningBackground:deficitdynamiclargeproportioncontinueexperienceevenphaseHoweverstudiesexaminedmultipleaspectsevidencesuggestsinvolveneuralmechanismsMethods:Parallelmeasureseffort-basedexpenditureEEfRTself-reportquestionnairesapplied6146healthycontrolspercentageshardtaskchoicesusedassessneurocognitivefunctionevaluatedexploredResults:reportedseveresignificantlylowerespeciallycognitive-effortwhereasassociatedexpressionPersonalSocialPerformanceScalePSPscoresConclusion:PatientsphysicallyreducedlesswillingmakeindicaterepresentdisparateneuropsychologicalprocessescloselyrelatedAbnormalhedonicschizophrenia:RelationshipsCognitionSchizophrenia

Similar Articles

Cited By